Familial Mediterranean fever (FMF) is a recessive autoinflammatory disease commonly found in the Mediterranean populations. Genetic diagnosis has developed since the discovery of the causative gene MEFV in 1997. As many patients could not be confirmed genetically by routine exon screening, we searched for mutations in the 5 0 -flanking region of this gene. Using denaturing gradient gel electrophoresis, we screened DNA from 108 patients with clinical FMF and 91 asymptomatic individuals. We found six novel sequence variants in a region extending À825 bp upstream of the first translated codon. To investigate the potential role of these variants in altering MEFV gene expression, we first characterized the MEFV promoter. Promoter mapping assays revealed that the region located between nucleotides À949 and À152 of the initiation codon was important for regulating expression of the gene. We identified a putative enhancer element between À571 and À414. Investigation of the sequence variants found in two patients demonstrated that c.À614C4G resulted in a 70% decrease in promoter activity, whereas c.À382C4T induced a 100% increase in activity, when compared to the wild type. We observed specific DNA-protein binding to both wild-type sites, suggesting that transcription factors may bind to these sequences to modulate MEFV expression.
Introduction
Familial Mediterranean fever (FMF, OMIM accession number: 249100) is one of the most frequent hereditary diseases in Mediterranean countries. It particularly affects Armenians, Arabs, Non-Ashkenazi Jews and Turks with a carrier rate ranging from 1:3 to 1:10. 1 The gene responsible for this disorder, MEFV (MEditerranean FeVer) is located on the short arm of chromosome 16 . It was simultaneously and independently identified in 1997 by two consortia. 2, 3 The initial discovery of five founding mutations, the commonest being M694 V, was rapidly followed by reports on rare or private mutations, as well as variants also found in control chromosomes. 1 To date, more than 170 sequence variants have been recorded in a dedicated online database (INFEVERS, http://fmf.igh.cnrs.fr/infevers) 4, 5 but few functional studies are available. As FMF diagnosis was only based on nonspecific clinical grounds until that time, researchers and clinicians anticipated that FMF diagnosis would be revolutionized by this major discovery. However, hopes were progressively tempered by the fact that 30-80% patients with clinical criteria were found to be free of MEFV mutation, or were simple carriers. In most laboratories, routine genetic diagnosis of FMF consists of screening for mutation hot spots (exons 2 and 10). Systematic sequencing of all exons and boundaries has provided no significant improvement. 6 A growing number of studies have increased our understanding of the MEFV function. The protein it encodes, called Pyrin or alternatively Marenostrin (P/M), is likely involved in regulating the production and secretion of proinflammatory cytokines (for example, interleukin (IL)-1b), and apoptosis. [7] [8] [9] [10] [11] Indeed, P/M binds several proteins through homotypic interactions. Its N-terminal PyD (pyrin domain) binds the PyD of ASC (apoptosis-associated Speck-like protein with a CARD), 9 an inflammasome component which itself is able to bind the CARD domain of pro-caspase-1, provoking its activation into active caspase-1. Caspase-1 in turn cleaves the IL-1b precursor to its active secreted form, a highly proinflammatory and pyrogenic cytokine. The association of wild-type P/M with ASC via its PyD is thought to downregulate the inflammatory response. Caspase-1 activation and IL-1b secretion are increased in mice expressing a truncated form of P/M. 7 However, this interaction does not explain the effects of mutations found in FMF patients in the 3 0 -terminal B30.2/SPRY (SP1a and RYnidine receptor) domain. A recent study demonstrated that the P/M SPRY domain interacts directly with both caspase-1 and its substrate pro-IL-1b, thereby blocking their proinflammatory activity. 10 MEFV is expressed in granulocytes, cytokine-activated monocytes, dendritic cells and fibroblasts derived from skin, peritoneum and synovium. 12, 13 Previous work by our group as well as others has demonstrated diminished levels of MEFV transcripts in leukocytes from FMF patients. 14, 15 Thus far, only one paper has addressed the possibility of mutations in the 5 0 -flanking region of the MEFV gene in FMF patients, but without yielding any positive results. 16 To address whether sequence variants in this region could be involved in FMF pathophysiology, we studied and found new variants in the 5 0 -flanking region of the MEFV gene in a series of patients with clinical but genetically unconfirmed FMF. We then characterized the normal 5 0 -flanking region of the MEFV gene to investigate whether variants in the MEFV promoter could alter transcription of the gene. We identified a modified transcriptional activity of the MEFV promoter in two patients who had no demonstrable exonic mutations but carried new variants in the 5 0 -flanking region.
Results
Identification of new variants in the MEFV 5 0 -flanking region We screened a series of 198 DNAs from our library of FMF families for possible promoter mutations. We selected probands with typical FMF symptoms for whom we could not confirm the disease genetically through our routine molecular screening of the MEFV gene. Asymptomatic relatives were also investigated to discriminate polymorphisms from putative new true mutations. Using denaturing gradient gel electrophoresis (DGGE) followed by sequencing characterization, we identified six unreported heterozygous sequence variants (c.À792C4T, c.À751A4G, c.À740C4T, c.À614C4G, c.À382C4T, c.À330G4A) in eight unrelated families (Table 1) . Only the three latter variants were found in typical FMF patients. The c.À330G4A sequence variant was located in trans to an exonic mutation (p.M694V). All exons and intronic boundaries from the two patients with the sequence variants c.À614C4G and c.À382C4G were completely sequenced, but no other MEFV mutation was detected.
Characterization of the normal MEFV 5 0 -flanking region We first characterized the promoter region of the wildtype MEFV gene (Figure 1a ) before investigating the possible role of the newly identified sequence variants in FMF pathophysiology. To determine the promoter activity of the MEFV gene, several 5 0 -flanking sequences with nested deletions were inserted into the pGL3 basic vector. In the SW-480 cell line constitutively expressing MEFV, maximal promoter activity was obtained with the longest (À949/À1) fragment which displayed 20 times more luciferase activity than the background activity measured with the empty pGL3 basic vector (Figure 1b) . The promoter activity decreased dramatically to 40% when the 5 0 -construct was shortened from À949/À1 to À288/À1. The lowest luciferase activity was observed for the À152/À1 and À92/À1 constructs. These results indicate that the promoter of the MEFV gene is located within the À288 bp upstream of the translation initiation codon. Very low luciferase expression similar to that of the empty pGL3 basic vector was detected for all these constructs when we transfected them into HEK293 cells which do not constitutively express MEFV (data not shown). This proximal promoter portion seems therefore to be tissue specific.
To localize important regulatory regions, we cloned various fragments excluding the minimal promoter region we have just characterized (nucleotide À1 to À288) into the pGL3-enhancer reporter vector and transfected the constructs into SW-480 cells. The longest fragments (À949/À288, À770/À288, À571/À288) exhibited no important modifications in luciferase expression, whereas the À414/À288 construct displayed three times less luciferase activity than the À571/À288 construct, suggesting a putative enhancer element upstream of the translational start codon between nucleotide À571 and À414 (Figure 1c ). 0 -sequences encompassing the concerned MEFV region in the pGL3 luciferase reporter vector. The vector containing c.À382C4T displayed a 70% decreased activity as compared to the one containing the wild-type sequence (Figure 2c ), whereas the vector harboring the c.À614C4G showed an almost 100% increase in luciferase activity ( Figure 2f ). These results suggest that both sequence changes alter MEFV expression and that the cytosines at positions À382 and À614 may be part of critical MEFV regulatory binding sites. It is noteworthy that these cytosines are located close to the putative enhancer sequences (À571/À414) we previously determined.
To assess protein binding to the 5 0 -flanking region of these two single nucleotide polymorphisms (SNPs), we performed electrophoretic mobility shift assay (EMSA) using nuclear extracts from the MEFV expressing SW-480 cell line. Complexes were detected with wild-type probes for each variant (Figure 3a and b), suggesting that proteins bind to these MEFV (À382 and À614) regions. We next examined the specificity of the DNA-protein interaction using competitive gel band shift assays. For both of these regions, the shifted band sharply disappeared upon competition with an excess of unlabeled wild-type oligonucleotide. However, this did not happen 
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C Notarnicola et al series of 36 Turkish patients with no coding region polymorphisms. 16 We identified six unreported SNPs located within 1000 bp of the initiation codon.
To assess the functional significance of the new SNPs, we first isolated and characterized the 5 0 -flanking region of the MEFV gene cloned into a luciferase expression vector. The promoter region proven sufficient to confer a minimal expression level of luciferase after transfection in SW-480 cells was mapped to a region within the first 288 bp of the translation initiation codon. The highest expression levels were obtained with constructs from position À288. These results are consistent with a previous study by Papin et al who showed that 243 bp of the 5 0 -flanking region of the human MEFV gene are sufficient to direct high level expression of MEFV in tumor necrosis factor-a (TNFa)-treated cells. They demonstrated that TNFa-induced expression of MEFV is dependent on the interaction of nuclear factore-kB (NFkB) p65 with C/EBPb, which binds to evolutionarily conserved sites located in the human promoter at positions À163 and À55 of the expression start site, respectively (À204 and À96 of the translation initiation codon). Papin et al. suggested that this C/EBP-NFkB interaction may represent a key step in the control of an inflammatory response that is abnormally high in this disease. We could not identify patients with mutations in or close to either of the two NFkB and C/EBPb regions to support this hypothesis.
We have also shown that the region between À571 and À414 contains a putative enhancer element. Two of the six new sequence variants identified in this study, c.À382C4T and c.À614C4G, are close to this enhancer and were found in two patients with typical FMF symptoms (recurrent fever with an onset occurring in the first decade, abdominal pain and arthralgia, good response to colchicine). These variants are unlikely to be the direct cause of FMF because they did not clearly segregate with the disease in our families. No other MEFV mutation was found in our patients suggesting that intronic mutations or genetic heterogeneity could contribute to disease development. However, c.À382C4T and c.À614C4G may accentuate or modulate the phenotype. Indeed, as supported by transfection experiments, the c.À382C4T presented a diminished activity as compared to the wild type, whereas, in contrast, c.À614C4G activated MEFV promoter expression. By modifying the promoter basal activity of the MEFV gene, these variants might, respectively, modify the activity of the putative (À571/ À414) enhancer element either positively or negatively (Figure 4) . Using EMSA experiments, we observed specific DNA-protein complexes at both À382 and À614 wild-type regions, indicating that nuclear protein(s) are able to bind to these sequences and perhaps contribute to the regulation of enhancer activity.
To assess whether these SNPs might be part of consensus-binding sites for known transcription factors, we analyzed the 5 0 -flanking region in the transcription factor database MATINSPECTOR. Cytosines 382C and 614C are located within the consensus sequence of a potential binding site for SP-1 and PU-1, respectively ( Figure 1a) . A powerful activator of gene transcription in many cell types, 17 SP-1 binds and activates the promoters of a large number of important myeloid genes, despite being expressed ubiquitously. There is growing evidence that ETS (E26 transformation-specific sequence) factors are also essential in regulating the immune system, activating the transcription of genes associated with pathogen and tumor defense. 18 PU-1 is the main member of the ETS family and has been identified as critical for maximal activity of the downstream IL-18 promoter. Additional supershift combined with chromatin immunoprecipitation experiments will be required to definitively confirm that these two putative transcription factors are able to bind to the endogenous 5 0 -flanking region of the MEFV gene and regulate MEFV gene transcription.
In conclusion, this work has identified the first mutations present outside of the MEFV gene open reading frame, and demonstrated that two of them may interfere with the regulation of the enhancer activity at nucleotide positions À571 and À414.
Materials and methods

Screening of MEFV variants in FMF patients and controls
Our laboratory has provided routine genetic diagnosis of FMF since the discovery of the gene in 1997. Our basic strategy includes molecular exploration of the two well known mutational hot spots of the MEFV gene, exon 2 and exon 10. A series of 108 patients with clinical, but genetically unconfirmed, FMF was further explored for mutations in the 5 0 -flanking region using DGGE analysis. A set of primers was designed to amplify three overlapping fragments covering the region from nucleotides À825 to þ 40 from the A of the initiation codon ( Table 2) . The amplification products were subjected to DGGE on a 6.4% polyacrylamide gel containing a linearly increasing denaturant concentration of 30-80%. The gels were run at 180 V and 62 1C for 6 h. Samples with altered migrations as compared to controls were systematically Figure 4 Hypothetical organization of the MEFV 5 0 -flanking region. The two 5 0 -regions critical for MEFV gene regulation identified in this study, i.e., the promoter and an enhancer element, are depicted as gray boxes. The two new MEFV sequence variants c.À614C4G and c.À382C4T are located on both sides of this putative enhancer and display opposite effects on the promoter activity. These two sites may therefore contribute to the gene regulation.
MEFV promoter
Characterization of new MEFV promoter mutations C Notarnicola et al sequenced in both directions. Furthermore, we screened 90 asymptomatic family members using the same approach. As our patients were from various Mediterranean populations, the nontransmitted chromosomes constituted the ethnically matched control group. Phase was established through analysis of the parents and delineation of haplotypes after examination of a set of linked microsatellites as described previously. 19 The project was approved by the local ethical committee and all individuals signed an informed consent.
Construction of reporter plasmids for promoter analysis
A series of reporter plasmids containing various lengths of the 5 0 -flanking region of the MEFV gene (Genbank accession number: AF111163) were generated by inserting genomic fragments obtained by PCR reactions into a pGL3-Basic vector (Promega Corp., Charbonnieres, France). This vector contains a modified firefly luciferase coding sequence upstream of the SV40 late poly(A) signal and neither eukaryotic promoter nor enhancer sequences. For directional cloning, primers designed to amplify and clone the MEFV promoter sequences were flanked at the 5 0 -ends either by a synthetic KpnI/NheI or HindIII restriction site ( Table 2 ). The PCR products were restricted with KpnI/NheI and HindIII endonucleases then ligated into the vector, immediately upstream of the luciferase reporter gene. Mutant reporter plasmids were generated by PCR from the genomic DNA of two FMF individuals previously found to be heterozygous for the c.À382C4T or c.À614C4G sequence variants. The integrity and accuracy of the wild-type or mutated constructs were checked by direct DNA sequencing on an Applied Biosystems 377 automated sequencer.
Cell transfection and transient gene expression assays
Plasmids used for transfection were purified using AX100 cartridges of Nucleobond AX system (MachereyNagel). Human colon adenocarcinoma (SW-480) cells were chosen for their endogenous expression of MEFV. Human Embryonic Kidney (HEK-293) cells, which do not express MEFV were used as a control. Cells were plated at a density of 5 Â 10 4 cells per well in 24-well plates, 24 h before transient transfections. When cells reached 50-70% confluence, they were cotransfected with 0.4 mg of plasmid reporter and 40 ng of internal control pRL-TK containing Renilla luciferase (Promega Corp.) driven by an HSV-TK promoter to normalize transfection efficiency. The pGL3-Basic or the pGL3-enhancer vectors were used as negative controls in the promoter experiments or the search for regulatory regions, respectively. The pGL3 constructs were transfected into SW-480 and HEK-293 cells using Lipofectamine Plus reagent (Gibco BRL, Invitrogen, Cergy Pontoise, France) according to the manufacturer's recommendations. Cells were grown for an additional 48 h, washed twice in phosphate-buffered saline, lysed in 200 ml of passive lysis buffer (Promega Corp.) and centrifuged briefly to remove cell debris. 10 ml of cleared lysate was assayed sequentially for firefly luciferase activity and Renilla luciferase activity using the Dual Luciferase Reporter Assay System (Promega Corp.) according to the manufacturer's specifications. Luminescence measurements were performed on a Lumat LB9501 luminometer (Berthold, Wilbad, Germany). Firefly luciferase activity was normalized to Renilla luciferase activity. Experiments were performed in triplicate, and each set of transfections was repeated at least twice. The luciferase activities are expressed as the mean value±s.e. relative to pGL3-Basic.
Electrophoretic mobility shift assay DNA sequences of synthetic oligonucleotides covering the region À394 bp to À368 bp and À626 bp to À602 bp of both the wild-type and mutated MEFV promoter were designed for use as probes and competitors (Table 2) . Appropriate sense and antisense strand pairs were annealed by heating at 85 1C for 2 min in 40 ml of annealing buffer (67 mM Tris-Hcl (pH 7.5), 13 mM MgCl2, 1.3 mM EDTA, 1.3 mM spermidine and 6.7 mM dithiothreitol) and cooling in two steps at 65 1C for 15 min followed by 37 1C ) using T4 polynucleotide kinase (Roche Applied Science, Meylan, France) according to the manufacturer's instructions, and separated from free nucleotides by QIAquick Nucleotides Removal kit (Qiagen, Courtaboeuf, France). Nuclear extracts were prepared from SW480 cells with Nuclear Extract Kit (Active Motif, Rixensart, Belgium) and quantitated by the BCA assay (Pierce, Rockford, USA). The binding reaction was performed by preincubating 10 mg of nuclear proteins with 0.5 mg of poly(dI-dC).poly (dI-dC) (GE Healthcare, Orsay, France) in 20 ml of buffer containing 20 mM HEPES (pH 8), 100 mM KCl, 20% glycerol, 0.2 mM EDTA, 0.5 mM PMSF and 0.5 mM dithiothreitol, for 15 min at room temperature. The end-labeled probes (1 Â 10 4 c.p.m.) were then added and the incubation was continued for 30 min at room temperature. Protein-bound probe and free probe were separated by electrophoresis through a 5% nondenaturing polyacrylamide gel in 0.5 Â TBE buffer (89 mM Tris Borate, 2 mM EDTA, pH8.0) for 1 h at 25 mA; the gel was then dried and autoradiographed with an intensifying screen. The specificities of protein-DNA complexes were analyzed by competition experiments, in which different molar excesses of consensus or mutant unlabeled competitor DNA were incubated with the reaction mixture for 20 min before the addition of the radiolabeled probe.
